№ 3 (188) 2024 р. С. 57–64

МІСЦЕ ПАРАОКСОНАЗИ В ОКСИДАНТНО-АНТИОКСИДАНТНІЙ СИСТЕМІ У РАЗІ КОМОРБІДНОСТІ ХРОНІЧНОГО ОБСТРУКТИВНОГО ЗАХВОРЮВАННЯ ЛЕГЕНЬ (ОГЛЯД ЛІТЕРАТУРИ)

Н. П. Масік, О. І. Масік, В. В. Килимчук, О. І. Мазур, Н. С. Недорезанюк, Е. М. Знаміровська

Вінницький національний медичний університет імені М. І. Пирогова, Вінниця, Україна

DOI 10.32782/2226-2008-2024-3-10

На підставі проведеного аналізу літератури встановлено, що в основі патологічних змін у разі ХОЗЛ лежать хронічний системний запальний процес низької інтенсивності та окислювальний стрес (ОС). Посилене утворення та вивільнення активних форм кисню (АФК) призводить до прогресуючого посилення процесів перекисного окислення ліпідів (ПОЛ) та окиснювальної модифікації білків і ліпопротеїдів. Одним із ферментів антиоксидантної системи (АОС) є параоксоназа (PON), яка пов’язана з мітохондріями, як основним джерелом АФК. PON людини включає три кальцій-залежні естерази: PON1, PON2 і PON3, які по-різному проявляють протизапальні, антиоксидантні, антиатерогенні та детоксикаційні властивості. PON1 можна розглядати як діагностичний маркер оксидантно-антиоксидативного дисбалансу у разі ХОЗЛ, асоційованого із серцево-судинними захворюваннями.

Ключові слова: хронічне обструктивне захворювання легень (ХОЗЛ), коморбідність із серцево-судинними захворюваннями, запалення, окислювальний стрес, антиоксидантна система, параоксоназа.

ЛІТЕРАТУРА

  1. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2022 Report. Available from: https://chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://staging.goldcopd.org/wp-content/ uploads/2021/12/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf.
  2. Feshchenko YI, Gavrysyuk VK, Dziublyk AY et al. Adapted clinical guideline: chronic obstructive pulmonary disease. Pulmonol. J. 2020; 3: 5–36. doi: 10.31215/2306-4927-2020-109-3-5-36 (in Ukrainian).
  3. Cho WK, Lee CG, Kim LK. COPD as a Disease of Immunosenescence. Yonsei Med J. 2019; 60(5): 407–413. https://doi. org/10.3349/ymj.2019.60.5.407.
  4. Peiser C. COPD and Inflammation [Internet]. A Compendium of Chronic Obstructive Pulmonary Disease. IntechOpen; 2023. http://dx.doi.org/10.5772/intechopen.107863.
  5. Taler-Verčič A, Goličnik M, Bavec A. The Structure and Function of Paraoxonase-1 and Its Comparison to Paraoxonase-2 and -3. 2020; 25(24): 5980. doi: 10.3390/molecules25245980.
  6. Buklioska Ilievska D., Minov J, Bushev J, Kochovska Kamchevska N. Low-grade systemic inflammation in patients with stable chronic obstructive pulmonary disease. Respiratio Medical Journal. 2019; 9 (1–2): 70–76. Available from: http://hdl.net/20.500.12188/18434.
  7. Lemko OI, Haysak MO, Reshetar DV. Comorbid conditions at chronic obstructive pulmonary disease: the questions under investigation and discussion. Part I. Ukrainskyi terapevtychnyi zhurnal. 2021; 1: 85–92. doi: http://doi.org/10.30978/ UTJ2021-1-85 (in Ukrainian).
  8. Ivchuk VV, Kovalchuk TA. Oxidant and antioxidant system in chronic obstructive pulmonary disease occupational etiology. Medychna ta klinichna khimiia. 21(2): 61–67. doi: 10.11603/mcch.2410-681X.2019.v.i2.10295 (in Ukrainian).
  9. Mahmood T, Singh RK, Kant S et al. Prevalence and etiological profile of chronic obstructive pulmonary disease in nonsmokers. Lung India: Official Organ of Indian Chest Society. 2017, 34 (2), 122. doi: 10.4103/0970-2113.201298.
  10. Lisetska IS, Rozhko MM. Biochemical indicators of oral fluid as markers for assessing the state of antioxidant-prooxidant systems in teenagers and young adults who smoke. Ukrainian Journal of Perinatology and Pediatrics. 2023; 1(93): 51–56. doi: 10.15574/PP.2023.93.51 (in Ukrainian).
  11. Bila I, Dzydzan О, Brodyak I, Sybirna N. Agmatine preventes oxidative-nitrative stress in blood leukocytes under streptozotocin-induced diabetes mellitus. Open Life Sciences. 2019; 14: 299–310. doi: 10.1515/biol-2019-0033.
  12. Kovalyova OM, Pasiieshvili TM. Biological and medical value of antioxidant protection system of the human body. Medytsyna sohodni i zavtra. 90(1): 21–32. https://doi.org/10.35339/msz.2021.90.01.03 (in Ukrainian).
  13. Bilyayeva OO, Osadchaya OI, Kryzhevskyi YeYe, Bitinsh AR. Substantiation of the use of antioxidant therapy in the complex conservative treatment of diabetic foot syndrome. Med. Chasopys. 2022. 1 (147) – I/II 1–5. doi: 10.32471/ umj.1680-3051.147.225667 (in Ukrainian).
  14. Korzhov VI, Zhadan VM, Polianska MO et al. Oxidant and antioxidant systems of the blood in experimental pulmonary emphysema. Аsthma and allergy. 2022; 4: 38–44. doi: 10.31655/2307-3373-2022-4-38-44 (in Ukrainian).
  15. Lorey MB, Öörni K, Kovanen PT. Modified Lipoproteins Induce Arterial Wall Inflammation During Atherogenesis. Front Cardiovasc Med. 2022; 9: 841545. doi: 10.3389/fcvm.2022.841545.
  16. Medina-Díaz IM, Ponce-Ruíz N, Rojas-García AE. et al. The Relationship between Cancer and Paraoxonase 1. Antioxidants (Basel). 2022; 11(4): 697. doi: 10.3390/antiox11040697.
  17. Khalil A, Fulop T, Berrougui H. Role of Paraoxonase1in the Regulation of High-Density Lipoprotein Functionality and in Cardiovascular Protection. Antioxid Redox Signal. 2021; 34(3): 191–200. doi: 10.1089/ars.2019.7998.
  18. Dziublyk OYa, Gumenyuk NI, Mhitaryan LS et al. Qualitative composition of blood lipoproteids in patients with inflammation of lower respiratory tract as a risk factor of atherosclerosis. Pulmonol. J. 2017; 3: 21–24 (in Ukrainian).
  19. Thompson EW, Demissei BG, Smith AM. et al. Paraoxonase-1 Activity in Breast Cancer Patients Treated with Doxorubicin with or Without Trastuzumab. JACC Basic Translational Science. 2022; 7(1): 1–10. doi: 10.1016/j.jacbts.2021.10.010.
  20. Lytvynets LY, Lytvynets-Golutiak UY, Lytvynets VY. Oksydatyvnyi stres i komponenty antyoksydantnoho zakhystu v mekhanizmakh formuvannia bronkhialnoi astmy u ditei. Naukovyi visnyk Uzhhorodskoho universytetu. Seriia «Medytsyna». 2022; 2(66), 106–110. doi: https://doi.org/10.32782/2415-8127.2022.66.20 (in Ukrainian).
  21. Watanabe J, Kotani K, Gugliucci A. Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis. Antioxidants (Basel). 2021; 10(12): 1891. doi: 10.3390/antiox10121891.
  22. Zinellu E, Zinellu A, Pau MC et al. Paraoxonase-1 in stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Minerva Respiratory Medicine. 2022; 61(3): 138–145. https://doi.org/10.23736/S2784-8477.22.01999-4.
  23. Aune D, Schlesinger S, Norat T, Riboli E. Tobacco smoking and the risk of heart failure: A systematic review and metaanalysis of prospective studies. Eur J Prev Cardiol. 2019; 26(3): 279–288. doi: 10.1177/2047487318806658.
  24. Shunmoogam N, Naidoo P, Chilton R. Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance. Vasc Health Risk Manag. 2018; 14: 137–143. doi: 10.2147/VHRM.S165173.
  25. Zhou WC, Qu J, Xie SY, Sun Y, Yao HW. Mitochondrial Dysfunction in Chronic Respiratory Diseases: Implications for the Pathogenesis and Potential Therapeutics. Oxid Med Cell Longev. 2021; 2021: 5188306. doi: 10.1155/2021/5188306.
  26. Kamimura D, Cain LR, Mentz RJ. et al. Cigarette Smoking and Incident Heart Failure: Insights From the Jackson Heart Study. Circulation. 2018; 137(24): 2572–2582. doi: 10.1161/CIRCULATIONAHA.117.031912.
  27. Albrengues J, Shields MA, Ng D. et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. 2018; 361(6409): 4227. doi: 10.1126/science.aao4227.
  28. Min J, Yang D, Kim M. et al. Publisher Correction: Inflammation induces two types of inflammatory dendritic cells in inflamed lymph nodes. Exp Mol Med. 2018; 50(4): 1. doi: https://doi.org/10.1038/emm.2017.292.
  29. Stasenko AA. Mistsevyi imunitet: textbook. NNTs «Instytut biolohii ta medytsyny». Kyiv. 2021. 153 р. (in Ukrainian).
  30. Lee PL, Lee KY, Cheng TM. et al. Relationships of Haptoglobin Phenotypes with Systemic Inflammation and the Severity of Chronic Obstructive Pulmonary Disease. Sci Rep. 2019; 9(1): 189. doi: 10.1038/s41598-018-37406-9.
  31. Hu Y, Li J, Lou B. et al. The Role of Reactive Oxygen Species in Arsenic Toxicity. Biomolecules. 2020; 10(2): 240. https:// doi.org/10.3390/biom10020240.
  32. Kryghna SI, Kievvskaia YiО, Kozar VV. The state of immunologic resistance in terms of experimental bacterial rhinitis and its pharmacological correction. Visnyik problem biologii I meditciny. 2018; 2(143): 137–140 (in Ukrainian).
  33. Albar Z, Albakri M, Hajjari J, et al. Inflammatory Markers and Risk of Heart Failure with Reduced to Preserved Ejection Fraction. Am J Cardiol. 2022; 167: 68–75. doi: 10.1016/j.amjcard.2021.11.045.
  34. Aimo A, Castiglione V, Borrelli C. et al. Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies. Eur J Prev Cardiol. 2020; 27(5): 494b510. doi: 10.1177/2047487319870344.
  35. Pasiyeshvili LM, Zhelezniakova NM, Pasiieshvili TM. Antioxidant system: norm and pathology. Skhidnoievropeiskyi zhurnal vnutrishnoi ta simeinoi medytsyny. 2021; 1: 40–46. doi: 10.15407/internalmed2021.01.040 (in Russian).
  36. Camps J, García-Heredia A, Hernández-Aguilera A, Joven J. Paraoxonases, mitochondrial dysfunction and non-communicable diseases. Chemico-Biological Interactions. 2016; 259(B): 382–387. https://doi.org/10.1016/j.cbi.2016.04.005.
  37. Cavallero A, Puccini P, Aprile V et al. Presence, enzymatic activity, and subcellular localization of paraoxonases 1, 2, and 3 in human lung tissues. Life Sciences. Volume 311, Part A, 2022. 121147. ISSN 0024-3205. https://doi.org/10.1016/j. lfs.2022.121147.
  38. Xu JH, Lu SJ, Wu P, et al. Molecular mechanism whereby paraoxonase-2 regulates coagulation activation through endothelial tissue factor in rat haemorrhagic shock model. Wound J. 2020; 17: 735–741. https://doi.org/10.1111/iwj.13329.
  39. Belovol AN, Topchiy II, Kirienko OM, Denisenko VP, Kirienko DA. Determination state of oxidative stress, pon1 activity and lipid spectrum in patients with diabetic nephropathies and hypertension disease. Eksperymentalna i klinichna medytsyna. 2018; 79 (2–3): 71–78. Available from: https://ecm.knmu.edu.ua/article/view/403 (in Ukrainian).
  40. Zhao XJ, Liu LC, Guo C. et al. Hepatic paraoxonase 1 ameliorates dysfunctional high-density lipoprotein and atherosclerosis in scavenger receptor class B type I deficient mice. Ann Transl Med 2021; 9(13): 1063. doi: 10.21037/atm-21-682.
  41. Durrington PN, Bashir B, Soran H. Paraoxonase 1 and atherosclerosis. Cardiovasc. Med. 2023; 10: 1065967. doi: 10.3389/fcvm.2023.1065967.
  42. Yemchenko Ya. The role of PPAR in the pathogenesis of psoriasis and obesity. VISNYK Ukrainska medychna stomatolohichna akademiia. 2019; 2(66): 224–229. doi: 10.31718/2077-1096.19.2.224 (in Ukrainian).
  43. Vatashchuk M, Hurza V, Bayliak M. Adapting of Spectrophotometric Assay of Paraoxonase Activity with 4-Nitrophenylacetate for Murine Plasma and Liver. Journal of Vasyl Stefanyk Precarpathian National University. 2023; 9(4): 6–14. doi: https: // doi.org/10.15330/jpnu.9.4.6-14.
  44. Vavlukis M, Vavlukis A, Krsteva K, Topuzovska S. Paraoxonase 1 gene polymorphisms in lipid oxidation and atherosclerosis development. Front Genet. 2022; 13: 966413. doi: 10.3389/fgene.2022.966413.
  45. Kunachowicz D, Ściskalska M, Kepinska M. Modulatory Effect of Lifestyle-Related, Environmental and Genetic Factors on Paraoxonase-1 Activity: A Review. Int J Environ Res Public Health. 2023; 20(4): 2813. doi: 10.3390/ijerph20042813.
  46. Mackness M, Sozmen EY. A critical review on human serum Paraoxonase-1 in the literature: truths and misconceptions. Turkish Journal of Biochemistry. 2021; 46(1): 3–8. https://doi.org/10.1515/tjb-2020-0186.
  47. Bacchetti T, Ferretti G, Carbone F, Ministrini S. Dysfunctional high-density lipoprotein: The role of myeloperoxidase and paraoxonase-1. Med. Chem. 2021; 28: 2842–2850. doi: 10.2174/0929867327999200716112353.
  48. Lipkan NG, Kuchmenko OB, Mkhitaryan LS. Inductive No-synthase activity and citrulline content in blood serum as markers of immuno-inflammatory activation and oxidative stress under chronic heart failure. Bulletin of Medical and Biological Research. 2021; 4(10): 46–52. doi: 10.11603/bmbr.2706-6290.2021.4.12492 (in Ukrainian)
  49. Soomro S. Oxidative Stress and Inflammation. Open Journal of Immunology. 2019; 9(1): 1–20. doi: 10.4236/oji.2019.91001.
  50. Parween F, Gupta RD. Insights into the role of paraoxonase 2 in human pathophysiology. J Biosci. 2022; 47: 4. https://doi. org/10.1007/s12038-021-00234-7.
  51. Manco G, Porzio E, Carusone TM. Human Paraoxonase-2 (PON2): Protein Functions and Modulation. Antioxidants. 2021; 10(2):256. https://doi.org/10.3390/antiox10020256.
  52. Li W, Kennedy D, Shao Z et al. Paraoxonase 2 prevents the development of heart failure. Free Radic. Biol. Med. 2018; 121: 117–126. https://doi.org/10.1016/j.freeradbiomed.2018.04.583.
  53. Shih DM, Meng Y, Sallam T et al. PON2 Deficiency Leads to Increased Susceptibility to Diet-Induced Obesity. Antioxidants (Basel). 2019; 8(1): 19. https://doi.org/10.3390/antiox8010019.
  54. Nagarajan A, Dogra SK, Sun L. et al. Paraoxonase 2 Facilitates Pancreatic Cancer Growth and Metastasis by Stimulating GLUT1-Mediated Glucose Transport. Mol Cell. 2017; 67(4): 685–701. doi: 10.1016/j.molcel.2017.07.014.
  55. Ritta MC, Baldez AM, Oliveira IO et al. Paraoxonase 1 serum activity in women: the effects of menopause, the C(-107)T polymorphism and food intake. Arch Endocrinol Metab. 2019; 63(3): 272–279. doi: 10.20945/2359-3997000000130.
  56. Yang X, Yang C, Friesel RE, Liaw L. Sprouty1 has a protective role in atherogenesis and modifies the migratory and inflammatory phenotype of vascular smooth muscle cells. 2023; 373: 17–28. doi: 10.1016/j. atherosclerosis.2023.04.007.
  57. Mahrooz A, Mackness M. Epigenetics of paraoxonases. Opin. Lipidol. 2020; 31: 200–205. doi: 10.1097/ MOL.0000000000000687.
  58. Djekic S, Vekic J, Zeljkovic A. et al. HDL Subclasses and the Distribution of Paraoxonase-1 Activity in Patients with ST-Segment Elevation Acute Myocardial Infarction. Int J Mol Sci. 2023; 24(11): 9384. doi: 10.3390/ijms24119384.
  59. Sansbury LB, Rothnie KJ, Bains C, Compton C, Anley G, Ismaila AS. Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England. J. Chron. Obstruct. Pulmon. Dis. 2021; 16: 2591–2604.
  60. Mehvari F, Imanparast F, Mohaghegh P, Alimoradian A. et al. Protective effects of paraoxonase-1, vitamin E and selenium, and oxidative stress index on the susceptibility of lowdensity lipoprotein to oxidation in diabetic patients with/without coronary artery disease. Eur J Med Res. 2023; 28(1): 300. doi: 10.1186/s40001-023-01254-9.
  61. Varadhan S, Venkatachalam R, Perumal SM, Ayyamkulamkara SS. Evaluation of Oxidative Stress Parameters and Antioxidant Status in Coronary Artery Disease Patients. Arch Razi Inst. 2022; 77(2): 853–859. doi: 10.22092/ARI.2022.357069.1965.
  62. Kotani K, Sakane N, Gugliucci A. Serum paraoxonase activity in familial hypercholesterolaemia. Arch Med Sci Atheroscler Dis. 2023; 8: 11–12. doi: 10.5114/amsad/160952.
Переглянути публікацію PDF